Skip to content

China Randomized Study of Screening for Prostate Cancer

China Randomized Study of Screening for Prostate Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102254
Enrollment
Unknown
Registered
2025-05-12
Start date
2025-05-12
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Intervention group:Collect venous blood for PSA screening tests in the intervention group. Biological specimens for testing should be properly preserved as required, testing should be completed within
those with PSA >= 4.0 ng/ml will undergo further clinical examination and intervention under the guidance of a clinician. Those with PSA < 4.0 ng/ml will have a test and follow-up every 2 years, conti
Control group:None

Sponsors

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
55 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Male2. Age 55-74 years3. Local registered permanent residents of the study area (living locally for six months or more)4. Sign the informed consent form and agree to participate in this study.

Exclusion criteria

Exclusion criteria: 1. History of cancer or received any type of cancer-related treatment (except for non-melanoma skin cancer); 2. PSA test conducted within the past 2 years; 3. Suffering from other serious illnesses that may affect the benefits of screening (such as stroke, severe lung disease, end-stage kidney disease, end-stage liver disease, severe heart failure, etc.); 4. Rectal examination, cystoscopy, catheterization or similar procedures performed within the last 48 hours; 5. Ejaculation occurred within the last 24 hours; 6. Suffering from prostatitis, or had prostatitis but cured for less than two weeks; 7. Taking medications for benign prostatic hyperplasia (such as finasteride, etc.).

Design outcomes

Primary

MeasureTime frame
Prostate cancer mortality;Detection of clinically insignificant prostate cancer;

Secondary

MeasureTime frame
Prostate cancer mortality;Incidence of prostate cancer ;clinically significant prostate cancer;Clinically advanced or high-risk prostate cancer;Difference in TNM stage;Survival for non-metastatic prostate cancer;All cancer mortality;All-cause mortality;Cost-effectiveness;

Countries

China

Contacts

Public ContactWanqing Chen

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

chenwq@cicams.ac.cn+86 132 4191 4190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026